Expression levels of ERBB2, ESR1, immune and proliferation signatures measured by RNASeq predict response to anti-HER2 treatment in the neoALTTO trial

Date 27 September 2015
Event European Cancer Congress 2015
Session Breast Cancer - Early Disease
Topics Breast Cancer, Early Stage
Presenter Sotiriou, C.